{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T01:06:30Z","timestamp":1780707990791,"version":"3.54.1"},"reference-count":26,"publisher":"Japanese Circulation Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2019,6,25]]},"DOI":"10.1253\/circj.cj-19-0158","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T22:05:22Z","timestamp":1558476322000},"page":"1520-1527","source":"Crossref","is-referenced-by-count":24,"title":["Real-World Effectiveness and Tolerability of Tolvaptan in Patients With Heart Failure\u3000\u2015 Final Results of the Samsca Post-Marketing Surveillance in Heart Failure (SMILE) Study \u2015"],"prefix":"10.1253","volume":"83","author":[{"given":"Koichiro","family":"Kinugawa","sequence":"first","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Intensive Care Unit, Nippon Medical School Musashi-Kosugi Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Inomata","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kitasato University Kitasato Institute Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moriyoshi","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Pharmacovigilance, Otsuka Pharmaceutical Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Shimakawa","sequence":"additional","affiliation":[{"name":"Otsuka Pharmaceutical Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Fukuta","sequence":"additional","affiliation":[{"name":"Otsuka Pharmaceutical Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Okura Y, Ramadan MM, Ohno Y, Mitsuma W, Tanaka K, Ito M, et al. Impending epidemic: Future projection of heart failure in Japan to the year 2055. <i>Circ J<\/i> 2008; 72: 489\u2013491.","DOI":"10.1253\/circj.72.489"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Sato N, Kajimto K, Keida T, Mizuno M, Minami Y, Yumino D, et al. Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND registry). <i>Circ J<\/i> 2013; 77: 944\u2013951.","DOI":"10.1253\/circj.CJ-13-0187"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Ahmad T, Jackson K, Rao VS, Tang WHW, Brisco-Bacik MA, Chen HH, et al. Worsening renal function in patients with acute heart failure undergoing aggressive diuresis is not associated with tubular injury. <i>Circulation<\/i> 2018; 137: 2016\u20132028.","DOI":"10.1161\/CIRCULATIONAHA.117.030112"},{"key":"4","unstructured":"4. Guidelines for diagnosis and treatment of acute and chronic heart failure (JCS 2017\/JHFS 2017 [in Japanese]). https:\/\/www.mhlw.go.jp\/file\/05-Shingikai-10901000-Kenkoukyoku-Soumuka\/0000202651.pdf (accessed February 20, 2019)."},{"key":"5","unstructured":"5. Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. <i>J Pharmacol Exp Ther<\/i> 1998; 287: 860\u2013867."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Matsuzaki M, Hori M, Izumi T, Fukunami M; Tolvaptan Investigators. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: A phase III, randomized, double-blind, placebo-controlled study (QUEST study). <i>Cardiovasc Drugs Ther<\/i> 2011; 25: S33\u2013S45.","DOI":"10.1007\/s10557-011-6304-x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kinugawa K, Imamura T, Komuro I. Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients. <i>Clin Pharmacol Ther<\/i> 2013; 94: 449\u2013451.","DOI":"10.1038\/clpt.2013.147"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kinugawa K, Sato N, Inomata T, Shimakawa T, Iwatake N, Mizuguchi K. Efficacy and safety of tolvaptan in heart failure patients with volume overload: Interim results of post-marketing surveillance in Japan. <i>Circ J<\/i> 2014; 78: 844\u2013852.","DOI":"10.1253\/circj.CJ-66-0093"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kinugawa K, Inomata T, Sato N, Yasuda M, Shimakawa T, Bando K, et al. Effectiveness and adverse events of tolvaptan in octogenarians with heart failure: Interim analyses of Samsca post-Marketing surveillance In Heart faiLurE (SMILE Study). <i>Int Heart J<\/i> 2015; 56: 137\u2013143.","DOI":"10.1536\/ihj.14-332"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kinugawa K, Inomata T, Sato N, Yasuda M, Shimakawa T, Bando K, et al. Who needs longer tolvaptan treatment? An interim analysis from the Samsca post-marketing surveillance in heart failure (SMILE study). <i>Int Heart J<\/i> 2017; 58: 1\u20136.","DOI":"10.1536\/ihj.16-249"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kajimoto K, Sato N, Takano T; Investigators of the Acute Decompensated Heart Failure Syndromes (ATTEND) registry. Association of age and baseline systolic blood pressure with outcomes in patients hospitalized for acute heart failure syndromes. <i>Int J Cardiol<\/i> 2015; 191: 100\u2013106.","DOI":"10.1016\/j.ijcard.2015.04.258"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Imamura T, Kinugawa K, Shiga T, Kato N, Muraoka H, Minatsuki S, et al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients: Association between non-responders and chronic kidney disease. <i>Circ J<\/i> 2013; 77: 397\u2013404.","DOI":"10.1253\/circj.CJ-12-0971"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Imamura T, Kinugawa K, Fujino T, Inaba T, Maki H, Hatano M, et al. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. <i>Circ J<\/i> 2014; 78: 2240\u20132249.","DOI":"10.1253\/circj.CJ-14-0244"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kim SR, Hasunuma T, Sato O, Okada T, Kondo M, Azuma J. Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: Results of single- and multiple-dose studies in healthy Japanese male volunteers. <i>Cardiovasc Drugs Ther<\/i> 2011; 25(Suppl 1): S5\u2013S17.","DOI":"10.1007\/s10557-011-6299-3"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Inomata T, Izumi T, Matsuzaki M, Hori M, Hirayama A; Tolvaptan Investigators. Phase III clinical pharmacology study of tolvaptan. <i>Cardiovasc Drug Ther<\/i> 2011; 25(Suppl 1): S57\u2013S65.","DOI":"10.1007\/s10557-011-6349-x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kinugawa T, Sato N, Inomata T, Yasuda M, Shibasaki Y, Shimakawa T. Novel risk score efficiently prevents hypernatremic event by tolvaptan in patients with heart failure. <i>Circ J<\/i> 2018; 25: 1344\u20131350.","DOI":"10.1253\/circj.CJ-17-0986"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. <i>N Engl J Med<\/i> 2012; 367: 2407\u20132418.","DOI":"10.1056\/NEJMoa1205511"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Madan VD, Novak E, Rich MW. Impact of change in serum sodium concentration on patients hospitalized with heart failure and hyponatremia. <i>Circ Heart Fail<\/i> 2011; 4: 637\u2013643.","DOI":"10.1161\/CIRCHEARTFAILURE.111.961011"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Konishi M, Haraguchi G, Ohigashi H, Sasaoka T, Yoshikawa S, Inagaki H, et al. Progression of hyponatremia is associated with increased cardiac mortality in patients hospitalized for acute decompensated heart failure. <i>J Card Fail<\/i> 2012; 18: 620\u2013625.","DOI":"10.1016\/j.cardfail.2012.06.415"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Imamura T, Kinugawa K. Prognostic impacts of hyponatremia, renal dysfunction, and high-dose diuretics during a 10-year study period in 4,087 Japanese heart failure patients. <i>Int Heart J<\/i> 2016; 57: 657\u2013658.","DOI":"10.1536\/ihj.16-227"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ambrosy AP, Pang PS, Khan S, Konstam MA, Fonarow GC, Traver B, et al. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: Findings from the EVEREST trial. <i>Eur Heart J<\/i> 2013; 34: 835\u2013843.","DOI":"10.1093\/eurheartj\/ehs444"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Matsue Y, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, et al. Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction. <i>J Card Fail<\/i> 2016; 22: 423\u2013432.","DOI":"10.1016\/j.cardfail.2016.02.007"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Felker GM, Mentz RJ, Cole RT, Adams KF, Egnaczyk GF, Fiuzat M, et al. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. <i>J Am Coll Cardiol<\/i> 2017; 69: 1399\u20131406.","DOI":"10.1016\/j.jacc.2016.09.004"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Konstam MA, Kiernan M, Chandler A, Dhingra R, Mody FV, Eisen H, et al. Short-term effects of tolvaptan in patients with acute heart failure and volume overload. <i>J Am Coll Cardiol<\/i> 2017; 69: 1409\u20131419.","DOI":"10.1016\/j.jacc.2016.12.035"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Inomata T, Ikeda Y, Kida K, Shibagaki Y, Sato N, Kumagai Y, et al. Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment: Results from the K-STAR Study. <i>Circ J<\/i> 2017; 82: 159\u2013167.","DOI":"10.1253\/circj.CJ-17-0179"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Wang C, Xiong B, Cai L. Effects of tolvaptan in patients with acute heart failure: A systematic review and meta-analysis. <i>BMC Cardiovasc Disord<\/i> 2017; 17: 164.","DOI":"10.1186\/s12872-017-0598-y"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/83\/7\/83_CJ-19-0158\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T03:18:13Z","timestamp":1561778293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/83\/7\/83_CJ-19-0158\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,25]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-19-0158","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,25]]}}}